Willow active extract of the bark, called salicin, was isolated to its crystalline form in 1828 by Henri Leroux, a French pharmacist, and Raffaele Piria, an Italian chemist, who then succeeded in separating out the compound in its pure state. In 1897, Felix Hoffmann created a synthetically altered version of salicin (in his case derived from the "Spiraea" plant), which caused less digestive upset than pure salicylic acid. The new drug, formally acetylsalicylic acid, was named Aspirin by Hoffmann's employer Bayer AG. This gave rise to the hugely important class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). Some of humans'
Acetohydroxamic acid Acetohydroxamic acid Acetohydroxamic acid (also known as AHA or by the trade name Lithostat) is a drug that is a potent and irreversible enzyme inhibitor of the urease enzyme in various bacteria and plants; it is usually used for urinary tract infections. The molecule is similar to urea but is not hydrolyzable by urease; it thus disrupts the bacteria's metabolism through competitive inhibition. In 1983 the US Food and Drug Administration approved acetohydroxamic acid (AHA) as an orphan drug for "prevention of so-called struvite stones" under the newly enacted Orphan Drug Act of 1983. AHA cannot be patented because it